Tekla Capital Management as of Dec. 31, 2012
Portfolio Holdings for Tekla Capital Management
Tekla Capital Management holds 61 positions in its portfolio as reported in the December 2012 quarterly 13F filing
Company (Ticker) |
Portfolio Weight |
Valued At |
Change in Shares |
Share Count |
Share Price |
---|---|---|---|---|---|
Gilead Sciences (GILD) | 8.8 | $55M | 752k | 73.45 | |
Regeneron Pharmaceuticals (REGN) | 8.5 | $53M | 311k | 171.07 | |
Celgene Corporation | 7.3 | $46M | 583k | 78.72 | |
Biogen Idec (BIIB) | 5.1 | $32M | 219k | 146.67 | |
Alexion Pharmaceuticals | 5.0 | $31M | 330k | 93.81 | |
Mylan | 3.4 | $22M | 781k | 27.48 | |
Perrigo Company | 3.4 | $21M | 203k | 104.03 | |
Puma Biotechnology (PBYI) | 3.3 | $21M | 1.1M | 18.75 | |
Hologic (HOLX) | 2.6 | $16M | 813k | 20.03 | |
Vertex Pharmaceuticals Incorporated (VRTX) | 2.5 | $16M | 380k | 41.94 | |
Shire | 2.5 | $16M | 168k | 92.18 | |
Onyx Pharmaceuticals | 2.2 | $14M | 185k | 75.53 | |
Medivation | 2.1 | $13M | 261k | 51.16 | |
Akorn | 2.0 | $13M | 936k | 13.36 | |
Merck & Co (MRK) | 1.9 | $12M | 297k | 40.94 | |
Ariad Pharmaceuticals | 1.9 | $12M | 619k | 19.18 | |
Teva Pharmaceutical Industries (TEVA) | 1.9 | $12M | 312k | 37.34 | |
Cubist Pharmaceuticals | 1.8 | $11M | 266k | 42.06 | |
Neurocrine Biosciences (NBIX) | 1.8 | $11M | 1.5M | 7.48 | |
Questcor Pharmaceuticals | 1.7 | $11M | 398k | 26.72 | |
Allergan | 1.6 | $10M | 109k | 91.73 | |
Aetna | 1.5 | $9.1M | 197k | 46.30 | |
Thermo Fisher Scientific (TMO) | 1.4 | $8.7M | 136k | 63.78 | |
Endo Pharmaceuticals | 1.3 | $8.4M | 318k | 26.27 | |
Covance | 1.3 | $8.1M | 140k | 57.77 | |
Watson Pharmaceuticals | 1.3 | $7.9M | 92k | 86.00 | |
Verastem | 1.2 | $7.8M | 885k | 8.79 | |
Alkermes (ALKS) | 1.2 | $7.7M | 417k | 18.52 | |
Impax Laboratories | 1.1 | $7.1M | 345k | 20.49 | |
Warner Chilcott Plc - | 1.1 | $7.1M | 586k | 12.04 | |
Incyte Corporation (INCY) | 1.1 | $7.0M | 421k | 16.61 | |
Alere | 1.0 | $6.5M | 352k | 18.50 | |
Illumina (ILMN) | 1.0 | $6.4M | 115k | 55.59 | |
Amarin Corporation (AMRN) | 1.0 | $6.4M | 790k | 8.09 | |
NPS Pharmaceuticals | 0.9 | $5.9M | 650k | 9.10 | |
McKesson Corporation (MCK) | 0.9 | $5.5M | 57k | 96.95 | |
Edwards Lifesciences (EW) | 0.8 | $5.2M | 58k | 90.17 | |
Baxter International (BAX) | 0.8 | $5.2M | 78k | 66.66 | |
IDEXX Laboratories (IDXX) | 0.8 | $5.2M | 56k | 92.79 | |
Nektar Therapeutics (NKTR) | 0.8 | $5.0M | 675k | 7.41 | |
ImmunoGen | 0.8 | $5.0M | 394k | 12.75 | |
UnitedHealth (UNH) | 0.7 | $4.5M | 82k | 54.24 | |
Accuray Incorporated (ARAY) | 0.7 | $4.3M | 672k | 6.43 | |
Intellipharmaceuticsintl Inc C | 0.7 | $4.3M | 1.7M | 2.47 | |
United Therapeutics Corporation (UTHR) | 0.6 | $3.9M | 73k | 53.42 | |
Acorda Therapeutics | 0.6 | $3.6M | 145k | 24.86 | |
Vivus | 0.6 | $3.5M | 262k | 13.42 | |
CVS Caremark Corporation (CVS) | 0.6 | $3.5M | 72k | 48.34 | |
Curis | 0.5 | $3.4M | 989k | 3.43 | |
Ironwood Pharmaceuticals (IRWD) | 0.4 | $2.3M | 208k | 11.09 | |
Dendreon Corporation | 0.3 | $2.0M | 377k | 5.28 | |
Keryx Biopharmaceuticals | 0.3 | $1.9M | 737k | 2.62 | |
Ceres | 0.3 | $1.9M | 427k | 4.54 | |
OncoGenex Pharmaceuticals | 0.2 | $1.5M | 113k | 13.12 | |
Celldex Therapeutics | 0.1 | $939k | 140k | 6.71 | |
Amgen (AMGN) | 0.1 | $864k | 10k | 86.32 | |
Endocyte | 0.1 | $541k | 60k | 8.99 | |
Icad (ICAD) | 0.1 | $362k | 76k | 4.79 | |
Cornerstone Therapeutics | 0.1 | $313k | 66k | 4.73 | |
Amicus Therapeutics (FOLD) | 0.0 | $186k | 69k | 2.68 | |
Sanofi Aventis Wi Conval Rt | 0.0 | $177k | 104k | 1.71 |